Antibodies induced by vaccination with purified chick embryo cell culture vaccine (PCECV) cross-neutralize non-classical bat lyssavirus strains.

Claudius Malerczyk (1) , Thomas Selhorst (2) , Noël Tordo (3) , Susan Moore (4) , Thomas Müller (2)

1 Novartis Vaccines and Diagnostics
2 FLI - Friedrich-Loeffler-Institut
3 Stratégies Antivirales
4 Kansas State University

Tissue-culture vaccines like purified chick embryo cell vaccine (PCECV) have been shown to provide protection against classical rabies virus (RABV) via pre-exposure or post-exposure prophylaxis. A cross-neutralization study was conducted using a panel of 100 human sera, to determine, to what extent after vaccination with PCECV protection exists against non-classical bat lyssavirus strains like European bat lyssavirus (EBLV) type 1 and 2 and Australian bat lyssavirus (ABLV). Virus neutralizing antibody (VNA) concentrations against the rabies virus variants CVS-11, ABLV, EBLV-1 and EBLV-2 were determined by using a modified rapid fluorescent focus inhibition test. For ABLV and EBLV-2, the comparison to CVS-11 revealed almost identical results (100% adequate VNA concentrations >or=0.5 IU/mL; correlation coefficient r(2)=0.69 and 0.77, respectively), while for EBLV-1 more scattering was observed (97% adequate VNA concentrations; r(2)=0.50). In conclusion, vaccination with PCECV produces adequate VNA concentrations against classical RABV as well as non-classical lyssavirus strains ABLV, EBLV-1, and EBLV-2.

Domaines: Microbiologie et Parasitologie

Claudius Malerczyk, Thomas Selhorst, Noël Tordo, Susan Moore, Thomas Müller. Antibodies induced by vaccination with purified chick embryo cell culture vaccine (PCECV) cross-neutralize non-classical bat lyssavirus strains.. Vaccine, 2009, 27 (39), pp.5320-5. ⟨10.1016/j.vaccine.2009.06.095⟩. ⟨pasteur-00460200⟩